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Abstract 
#e reasons for the lack of access to essential healthcare policies and medicines 
are manifold, but in many cases the high prices of drugs create a barrier to 
needed treatments in developing countries.1 #ese prohibitive drug prices 
are often the result of corporations in industrialized nations holding patents 
on the technology to produce their recently discovered medicine. Strong 
intellectual property rights were developed for pharmaceutical companies 
who invested in the creation of new medicines to receive the maximum pro$t 
from their innovation. However, the monopolization of these medicines’ 
production gives the corporation the ability to sell their product at a high 
cost, often unreachable for poor countries to a"ord. Governments in these 
developing countries have attempted to bring down the prices of medicines 
yet been blocked by industrialized countries who formulated the World Trade 
Organization Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
Agreement to set strong standards for the protection of intellectual property, 
1  Ellen Hoen, “TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, 
Doha and Beyond,” Chicago Journal for International Law, Vol. 3, no 1 (Spring 2002).
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including patents for pharmaceuticals.2 In addition, patents on genes, such 
as the case of Myriad Genetics’ ownership of the BRCA1 and BRCA2 genes 
restrict diagnostics, therapies, drug development and identi$cation of related 
cancers to be done solely by Myriad preventing patients from obtaining a 
second diagnostic opinion from an independent laboratory. Article 25 in the 
Universal Declaration of Human Rights states that “everyone has the right 
to a standard of living adequate for the health and well-being of himself and 
his family including medical care and the right to security in the event of 
sickness and disability.”3 #erefore denying individuals access to available 
lifesaving medicine for the sake of maximizing corporations pro$t is causing 
citizens in developing countries to su"er from a lack of adequate standard 
of health. To understand why patent laws have been predominantly looked 
at as a political economy issue and remain disproportionately unexamined 
under the human rights scope leads me to ask the following research question: 
Why are human rights laws not being applied to the restrictions imposed 
by global patent law? 
Real-World Observation
On April 27, 2015 the Royal Society of Medicine held a conference in 
London and produced a report stating that $ve billion people do not have 
access to safe, a"ordable surgical and anesthesia care when needed.4 Access 
is the worst in low-income and lower-middle-income countries, where nine 
of ten people cannot access basic surgical care.5 #is conference was held to 
examine how global surgery will be shaped in the future, publishing their 
$ndings in #e Lancet journal in order to educate developed countries on 
the role they ought to play to help combat this issue.6 #eir research stated 
that progress in global health over the past 25 years has not been uniform 
internationally with mortality and morbidity from common conditions 
2  Ibid. 
3  #e United Nations, Universal Declaration of Human Rights. 1948
4  Donald Mcneil, “Routine Operations Could Save Millions of Lives, If #ey Were Avail-
able,” !e New York Times, April 27, 2015.
5  Meara John, “Global Surgery 2030: Evidence and Solutions for Achieving Health, Welfare, 
and Economic Development.” !e Lancet, 386.9993 (2015): 569-624. 
6  “Global Surgery, Anesthesia, and Obstetrics: Shifting Paradigms and Challenging Genera-
tions,” !e Royal Society of Medicine, 2015.
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needing surgery growing in the world’s poorest regions.7 In the absence of 
surgical care, fatality rates are high for common, easily treatable conditions 
including appendicitis, hernia, fractures, obstructed labor, congenital anom-
alies, and breast and cervical cancer.  
Low and middle income countries are facing the burden of infectious dis-
ease, maternal disease, non-communicable diseases, and injuries all of which 
surgical and an anesthesia care are essential for treatment. When viewing 
the large projected increase in the incidence of cancer, road tra!c injuries 
and cardiovascular diseases in these low and middle income countries, the 
need for surgical services in these regions will continue to rise substantially 
from now until 2030.8 Despite the growing need, surgery was considered 
too complicated and expensive to be an integral part of public health in 
developing countries. #erefore, the Royal Society of Medicine decided to 
bring light to this issue. #e World Bank estimates that universal access to 
44 procedures would prevent 6% to 7% of all preventable deaths in low and 
middle income countries.9 With surgeries new found recognition as a cost 
e"ective public health intervention, providing access to essential surgical 
services and safe and timely medical care can only be achieved by addressing 
the weaknesses within the health care system. 
#e reasons for the lack of access to essential healthcare policies and medi-
cines are manifold, but in many cases the high prices of drugs create a barrier 
to needed treatments in developing countries.10 #ese prohibitive drug prices 
are often the result of corporations in industrialized nations holding patents 
on the technology to produce their recently discovered medicine. Strong 
intellectual property rights were developed for pharmaceutical companies 
who invested in the creation of new medicines to receive the maximum 
pro$t from their innovation. However, the monopolization of medicines’ 
production a"ords corporations with the ability to sell their product at a 
high cost, often unreachable for poor countries to a"ord. Governments in 
7  Op. Cit., fn. 5
8  Op. Cit., fn. 5
9  #e World Bank, “Surgery Could Save Millions of Lives in Developing Countries,” March 
26, 2015. 
10  Ellen Hoen, “TRIPS, Pharmaceutical Patents and Access to Essential Medicines: Seattle, 
Doha and Beyond,” Chicago Journal for International Law, Vol. 3, no 1 (Spring 2002).
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these developing countries have attempted to bring these prices down, yet 
have been blocked by industrialized countries who formulated the World 
Trade Organization Trade-Related Aspects of Intellectual Property Rights 
(TRIPS) Agreement, which set strong standards for the protection of intel-
lectual property, including patents for pharmaceuticals.11 Article 25 in the 
Universal Declaration of Human Rights states that “everyone has the right 
to a standard of living adequate for the health and well-being of himself and 
his family including medical care and the right to security in the event of 
sickness and disability.”12 #erefore, denying individuals access to available 
lifesaving medicine for the sake of maximizing corporations pro$t is causing 
citizens in developing countries to su"er from a lack of adequate standard 
of health. To understand why patent laws have been predominantly looked 
at as a political economy issue and remain disproportionately unexamined 
under the human rights scope leads me to ask the following research question: 
Why are human rights laws not being applied to the restrictions imposed 
by global patent law? 
Conventional Wisdom 
International conventional wisdom arrives at the same consensus, that people 
believe human rights should be a higher priority on the international agenda. 
#is consensus is displayed through the non-partisan poll conducted by 
World Public Opinion, which states that majorities in all nations surveyed 
express support for the United Nations playing an active role in promoting 
human rights and reject the argument that their intervention would be an 
improper interference in the internal a"airs of a country.13 Publics in most 
countries favor the UN playing a larger role than it presently does to promote 
human rights. In a second World Public Opinion survey, data suggests that a 
majority of individuals in 17 of the 21 nations polled say their government 
should abide by international law and reject the view that governments are 
not obliged to follow international laws when they con&ict with the national 
11  Ibid. 
12  #e United Nations, Universal Declaration of Human Rights. 1948.
13  “Polls Find Strong International Consensus on Human Rights,” World Public Opinion, 
December 7, 2010.
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interest.14 #is data proves an authoritative claim that the international 
community supports human rights laws as an international movement.
 However, current practices suggest that patent laws are restricting human 
rights through infringing on an individual’s right to health as stated in the 
Universal Declaration of Human Rights. Patents allow for monopolistic 
control over substances that are essential to research, medicine and pa-
tients – all things crucial in human rights plans.15 #e last decade has seen 
a dramatic expansion of intellectual property protection standards, both in 
their subject matter and scope of economic interests they protect. Due to 
the TRIPS agreement, intellectual property rights have been an economic 
issue in the world trading system with unexamined implications in a public 
health, education, or human rights sectors.16  #e surge of the human rights 
movement during post-World War II placed international patent law inter-
ests in the shadows while other issues emerged to the movement’s forefront, 
leaving them relatively unexplored. #is paper brings light to pharmaceutical 
patent laws under the scope of international human rights to identify the 
restrictions imposed by these intellectual property interests and the global 
implications they create. 
Methodology and Evidence 
To illustrate the impact of patent laws on the $eld of international human 
rights, this paper will use qualitative methodology in the form of case study 
research. #ese case studies will examine two speci$c restrictions imposed 
by patent laws: access to medicine and access to healthcare. #is paper will 
mostly utilize primary sources in order to obtain non-bias evidence to support 
my research $ndings. Examples of primary sources that will be included in 
this paper will be government reports, United Nations’ reports, World Bank 
reports and World Health Organization reports. My secondary evidence will 
be drawn from sources including the New York Times, #e Washington Post 
and scholarly journals.  
14  “People in 17 of 21 Nations Say Governments Should Put International Law Ahead of 
National Interest,” World Public Opinion, November 2, 2009.
15  Daniel Kevles, “Can #ey Patent Your Genes?,” !e New York Review, March 7, 2013.
16  Laurence Helfer, “Toward a Human Rights Framework for Intellectual Property,” UC 
Davis L. Rev, Vol. 40 (2006): 975.
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"eoretical Paradigm 
#e theory that best explains and frames my research question is international 
legal realism. In international law, legal realism’s core assumption is that rules 
and law that govern interstate behavior are based on the distribution of power 
between states.17 #is paradigm emphasizes that world politics are driven by 
the relative power positions of states and the laws they create.18 According to 
the theory’s founder Hans Morgenthau, “universal moral principles cannot 
be applied to the actions of states in their abstract universal formulation, but 
they must be $ltered through the concrete circumstances of time and place.”19 
#is analysis of the relationship between legal realism and ethics explains 
that realists are aware of the moral signi$cance of political action but are also 
aware of the tension between morality and the requirements of successful 
political action. Morgenthau introduces rationality to this theory de$ning 
rationality as a process of calculating the costs and bene$ts of all alternative 
policies in order to determine their utility and ability to maximize power.   
Given these assumptions, international legal realism will help explain my 
research question and research $ndings. #e primary assumption of interna-
tional legal realism being that politics are driven by the relative power of states 
frames the dynamic of developed nations’ power over developing nations in 
creating international patent laws. Realism’s assumption of states political 
power as the driving force for all outcomes in world politics helps to frame 
this papers examination of states laws e"ect on international human rights. 
#e theory’s aspect of rationality helps to examine international patent law 
as a political economy issue due to its innate relation to cost-bene$t analysis.
Conventional wisdom thinkers use the theoretical paradigm of liberalism 
to frame and explain their opinion on human rights issues and international 
intervention. #e fundamental principle of liberalism is that special interests 
rather than state interests prevail and that peace and cooperation are in the 
best interest of every state.20 #e founders of liberalism, Immanuel Kant and 
17  Professor Shelley L. Hurt, “#eoretical Paradigms of International Law,” POLS 426-01 
course reader (Spring 2015).
18  Ibid.
19  Julian Korab-Karpowicz, “Political Realism in International Relations”, !e Stanford 
Encyclopedia of Philosophy (Summer 2013 Edition), Edward N. Zalta (ed.).
20  Op. Cit., fn. 16
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Adam Smith, emphasize the importance of interdependence of states and 
non-state actors in implementing international institutions and reform.21 #is 
theory explains the conventional wisdoms rational of believing that human 
rights should be put before the states own interest. #e theory’s belief in 
interdependence between states frames these thinkers’ desire for increased 
action for human rights and United Nations intervention. Liberalism helps 
explain an ideal way of handling human rights issues while international 
legal realism frames the actual situation occurring due to the restrictions 
imposed by patent laws. 
Restrictions Imposed: Access to Medicine 
#e O!ce of the United Nations High Commissioner for Human Rights 
convened an expert conference on October 11, 2010 in Geneva, Switzerland 
to “exchange views on human rights considerations relating to the realization 
of access to medicines as one of the fundamental elements in achieving the 
full realization of the right of everyone to the highest attainable standard 
of physical and mental health.”22 During this conference Craig Mokhiber, 
speaking on behalf of the UN Human Rights o!ce, stated that “human rights 
law provides standards for access to medicine requiring that they are safe, 
a"ordable, of appropriate quality, and made available without discrimina-
tion.”23 He listed a number of steps that could be taken to achieve health as 
a fundamental human right including expanding access to o"-patent drugs 
and price control.
#e acknowledgement of patent protections as impeding access to med-
icine and therefore human rights standards is a central issue initially im-
posed by the 1994 TRIPS agreement. #e agreement states that all World 
Trade Organization (WTO) member states are obliged to grant patents to 
medical inventions to encourage innovation by assuring compensation to 
21  Juliet Kaarbo and James Ray, Global Politics (Boston: Cengage Learning, 2010).
22  United Nations Human Rights Council, “Promotion and Protection of All Human 
Rights, Civil Political, Economic, Social and Cultural Rights, Including the Right to Devel-
opment,” 12th Session. October 12, 2009. 
23  United Nations Human Rights, “Access to Medicines – Fundamental to the Right to 
Health,” November 5, 2010. 
paideia
18
recoup the high cost of developing new medicines.24 #ese patents on med-
icines give drug companies the right to prevent others from manufacturing 
their innovation, meaning that only brand name drugs are available for 20 
years from the $ling date. #erefore during these 20 years, arti$cially high 
prices can be charged.25 Some developing countries have viewed the TRIPS 
agreement as a barrier in their attempt to combat public health problems 
by restricting drug availability due to high cost of una"ordable medicine in 
countries whose health-care systems are often overwhelmed by HIV/AIDS 
and other infectious diseases.26 Without patent protection, the production 
of generic drugs drives the prices of medicines down to a"ordable levels. 
For example, Prozac which during its patent period sold for $2.50 per pill 
was produced by a generic manufacturer for only $0.25 a pill after its patent 
ended.27 #is large increase in the price of medicines due to patent law has 
a large e"ect on people in developing countries who cannot a"ord to buy 
these drugs, leaving many su"ering from treatable diseases. #is displays the 
con&ict between patent law and human rights due to restrictions on access 
to medicine through heavily increased prices, leaving millions of people 
in developing countries unable to achieve their right to health. #e Doha 
Declaration was intended to be a shield for developing countries against the 
repercussions of universalized intellectual property standards to drug access 
however; pharmaceutical patents are still creating a barrier. 
#e Doha Declaration was a 2005 amendment to the TRIPS agreement 
stating that developing countries could use compulsory licenses in situations 
of a national emergency to access life-sustaining medicines.28 Compulsory 
licenses are issued by governments to authorize the use or production of a 
24  Ian F. Fergusson, “#e WTO, Intellectual Property Rights, and the Access to Medicine 
Controversy,” (online report, U.S. Library of Congress, Congressional Research Service, 
December 12, 2006).
25  Wendy H. Schacht and John R. #omas, “Patent Law and Its Application to the Phar-
maceutical Industry: An Examination of the Drug Price Competition and Patent Term 
Restoration Act of 1984,” (online report, U.S. Library of Congress, Congressional Research 
Service, January 10, 2005). 
26  Op. Cit., fn. 22
27  Barry Robson and O.K. Baek, “#e Engines of Hippocrates: From the Dawn of Medicine 
to Medical and Pharmaceutical Information,” (Wiley, 1 edition, 2009): 475. 
28  Op. Cit., fn. 22
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patented item by a domestic party other than a patent holder in cases of 
extreme urgency or national emergency.29 Article 31 of the agreement limits 
the scope and duration of a compulsory license to address the circumstanc-
es for which the license is authorized and restricts production authorized 
by the compulsory license to the domestic market.30 According to former 
European Union trade negotiator Pascal Lamy “we have solved about 10% 
of the problem of access to medicines in developing countries through the 
WTO’s action.”31 Even with this amendment in place, developing nations 
have seldom made use of the &exibility of the TRIPS agreement. Even though 
a developing country with no manufacturing capability may use a compulsory 
license to obtain a product for a generic manufacturer in another country, 
the generic manufacturer in the second country may have no incentive to 
produce such limited quantities to poor countries. In addition, under many 
of the proposals the product would have to use distinguishable packaging 
with identi$able characteristics to avoid trade diversion to other markets.32 
Under such restrictions, it is not certain that a generic producer would un-
dertake the development and formulation costs for such a limited market.33 
#us, even though a compulsory license may be issued, the drugs may never 
be manufactured.  
#ailand provides an excellent example of why other countries have been 
reluctant to utilize compulsory licensing. When the country issued a number 
of compulsory licenses for antiretroviral drugs by Abbott’s Kaletra, the large 
pharmaceutical company was angered at #ailand for ‘ignoring the patent 
system.’ In response, Abbott Kaletra announced it would not be applying 
for license to sell seven of its newest products in #ailand.34 #ailand has 
since been repeatedly placed on a U.S. Trade Representative ‘priority watch 
29  Op. Cit., fn. 22
30  World Trade Organization, “Trade-Related Aspects of Intellectual Property,” 2015, p. 333. 
31  “WTO Drug Pact Lifts Trade Talks,” Wall Street Journal, September 2, 2003.
32  Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and 
Public Health, Note from the Chairman, Paragraph 2(b)(ii), December 16, 2002.
33  UK Commission on Intellectual Property, “Integrating Intellectual Property and Devel-
opment Policy,” September 2002, p. 45-46.
34  “Abbott to Withhold New Drugs from #ailand in Retaliation for Kaletra Compulsory 
License,” Aidsmap, March 15, 2007.
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list’ of countries seen to be committing intellectual property piracy.35 Due 
to the repercussions larger developed nations have the potential to impose; 
compulsory licensing has had little e"ect on widening developing countries 
access to medicine.
Even with a compulsory license provision in place, patents are still placing 
restrictions on international access to medicine. Although patents have ex-
pired on a number of $rst-line AIDS drugs making them available cheaply 
from generic makers, patents still exist on most new and second-line med-
icines complicating the provision of HIV treatment. #is is problematic as 
newer antiretroviral drugs are generally less toxic, making it easier to take 
and more e"ective at $ghting HIV.36 Drugs used to combat resistance are 
called second-line drugs and although the number of people in need of these 
drugs is expected to increase, the price of second-line drugs remains on av-
erage six times higher than drugs commonly used for $rst-line regimens.37 
One limitation of TRIPS is that the new, better drugs are only available in 
countries that have the capacity to cover the high cost, widening the access 
to treatment gap due to pro$t margins of large pharmaceuticals being put 
before public health.  
In February 2009, a shipment of second-line generic antiretroviral drugs 
was con$scated by Dutch customs authorities. #e 49kg of Abacavir sul-
fate tablets produced by an Indian company, Aurobindo, were bound for a 
treatment program in Nigeria.38 #e tablets were later released but the seizure 
highlights the tensions between the European Union’s rules on intellectual 
property rights and World Trade Organization rules concerning the produc-
tion of generic medicines.  
Legal showdowns have begun to arise against the drug industry in recent 
years highlighting the struggle for global health equity in this patent war. 
#is is highlighted in the 2013 landmark decision by the Indian Supreme 
Court whose ruling blocked global pharmaceutical giant Novaritis’ e"ort 
35  “U.S. Trade Representative Places #ailand on Priority Watch List in Annual Report,” 
Kaiser Health News, May 1, 2007.
36  “HIV/AIDS, TRIPS and Second-Line #erapy,” AVERT, 2014.
37  World Health Organization,“HIV Drug Resistance Fact Sheet,” April 2011.
38  “NIGERIA: Seizure of Drug Shipments #reatens ARV Access,” IRIN PlusNews, March 
13, 2009.
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to patent an updated version of its leukemia-treating drug.39 #is decision 
cleared the way for mass production of a much cheaper generic version to 
supply lifesaving medicines for much of the developing world. However, 
larger currently pending agreements such as the Trans-Paci$c Partnership 
Agreement (TTP), a free trade agreement involving the U.S. and 11 other 
Paci$c-Rim countries, contains intellectual property provisions designed to 
preempt trade barriers that protect access to medicine.40 If signed, the TPP 
would force all countries to grant additional drug patents, extending monopo-
lies on medicines beyond 20 years which will delay lower-cost versions of these 
medicines from entering the market.41 According to Rohit Malpani, Director 
of Policy and Analysis at Doctors Without Borders Access Campaign, “the 
intellectual property provisions of the TPP completely undermine the Obama 
Administration’s stated public health goals.”42 In addition, this would pave the 
way for drug industry giants to avoid the kind of public interest challenges 
at issue in the Indian court.43 Today, 26 million people worldwide are still 
without access to proper treatment, and the World Health Organization has 
recently pressed wealthy donor states for a major infusion of aid for medical 
treatment programs to meet their right to health.44 Yet, those same programs 
are sliding on a collision course with powerful pharmaceutical monopolies 
from patents. Under the global intellectual property protections, the world’s 
poorest patients, who line up to vaccinate their children from diseases that 
better-o" countries eradicated generations ago, are priced out of a medical 
market that thrives on the desire for wealth.
Restrictions Imposed: Access to Healthcare 
According to a 2005 study by the National Center for Biotechnology 
Information, nearly 20 percent of our approximately 23,000 human genes 
39  Rama Lakshmi, “India Rejects Novartis Drug Patent,” !e Washington Post, April 1, 2013.
40  “TPP Trade Deal Will Be Devastating for Access to A"ordable Medicines,” Doctors With-
out Borders, January 26, 2015. 
41  Ibid.
42  Ibid.
43  Michelle Chen, “Patents Against People: How Drug Companies Price Patients out of 
Survival,” Dissent Magazine, Fall 2013.  
44  Ibid. 
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have been patented.45 One particularly famous case involves Myriad Genetics 
patent ownership of two genes, BRCA1 and BRCA2, whose mutations can 
dramatically increase a woman’s chance of developing breast or ovarian can-
cer.46 Myriad was granted seven patents in 1997 over the sequenced BRCA1 
and BRCA2 genes, associated mutations and associated diagnostic tests to 
detect their presence. 47 #ese patents allowed Myriad to monopolize the 
diagnostic tests to look for such mutations as well as give the company a 
virtual lock on research and diagnostics of the BRCA1 and BRCA2 genes. 
Since the patent system was designed to grant certain rights to inventors in 
order to reward and encourage human inventiveness, existing law during 
this patents enactment allowed this infringement upon people’s access to 
healthcare solely because this was being looked at as an economic issue 
versus an ethical issue.  
In order to clarify and simplify U.S. law, the Patent Act of 1952 was created. 
#is act states that in order to qualify for a patent, an inventor must show 
that their innovation is useful, novel and nonobvious and something that is 
a process, machine, manufacture or composition of matter.48 In 1980, the 
Supreme Court of the United States decision in Diamond v. Chakrabarty 
set an important precedent for areas of patentability by ruling that laws of 
nature, physical phenomena, and abstract ideas are not patentable however, 
“manifestations of nature” are.49  Following this ruling’s guidelines, the Patent 
and Trademark O!ce (PTO) was able to begin issuing patents on three dif-
ferent versions of DNA isolated from the body to meet this manifestation of 
nature requirement. #e $rst is “complementary DNA” or cDNA which is 
constructed of only the gene’s base pairs which produce some of the amino 
acids that assemble into the body’s proteins placed in the same order as they 
occur in the native gene omitting the other gene’s base pairs.50 #e other two 
45  Kyle Jensen and Fiona Murray, “Intellectual Property Landscape of the Human Genome,” 
Science 310(5746):239-240 (October 14, 2005).
46  Wendy H. Schacht and John R. #omas, “Gene Patents: A Brief Overview of Intellectual 
Property Issues,” (online report, U.S. Library of Congress, Congressional Research Service, 
July 18, 2013).
47  Op. Cit., fn. 15
48  Op. Cit., fn. 46
49  Diamond v. Chakrabarty, 417 U.S. 303 (1980). 
50  Op. Cit., fn. 46
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patented versions of DNA comprised isolated fragments or the whole of the 
raw DNA in a gene. Myriad was granted patents meeting the “composition 
of nature” requirement due to its $ndings of the chemical structure of the 
BRCA genes as well as “method” claims covering processes for diagnosing 
breast cancer.51 Myriad’s patents encompass every conceivable use of the 
three types of DNA, including diagnostics, therapies, drug development and 
the identi$cation of other cancers involving either of the genes.52 However, 
these patents soon developed controversy over the ethical issue that Myriad’s 
monopolization on all aspects of research and diagnostic testing interfered 
with the progress of science and the delivery of healthcare services.  
In May 2009, the Association for Molecular Pathology (AMP) along with 
the American Civil Liberties Union (ACLU) and nineteen other plainti"s 
$led a lawsuit against Myriad Genetics Corporation seeking to overturn the 
patents on DNA isolated from two human genes, BRCA 1 and BRCA 2.53 
#e plainti"’s lawyers approached the suit as though it were a civil rights case, 
reaching beyond the technicalities of patent law to emphasize the human 
rights issue that the patents created which enabled Myriad to infringe the 
rights of biomedical scientists, physicians and patients. #ey contended that 
BRCA DNA, and by implication all human DNA, should not be eligible 
for patents as a matter of law since patients had su"ered harm from Myriad 
enforcing its BRCA patent in clinics and laboratories stopping others from 
using the genes for cancer research.54 Myriad’s monopolization prevented 
patients from obtaining a second diagnostic opinion from an independent 
laboratory and enabled it to charge a list price of almost $4,000 for a BRCA 
gene evaluation test, a price that many women can’t a"ord.55 Women were 
forced to trust one laboratory performing a single test to secure a diagnostic 
and inform treatment. Additionally, limiting gene-sequence based test services 
51  Timothy B. Lee, “You Can’t Patent Human Genes. So Why Are Genetic Testing Compa-
nies Getting Sued?” !e Washington Post, July 12, 2013. 
52  Op. Cit., fn. 15
53  John R. #omas, “Mayo v. Prometheus: Implications for Patents, Biotechnology, and 
Personalized Medicine,” (online report, U.S. Library of Congress, Congressional Research 
Service, November 6, 2012).
54  Op. Cit., fn. 15
55  Andrew Pollack, “After Patent Ruling, Availability of Gene Tests Could Broaden,” !e 
New York Times, June 13, 2013. 
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to a single provider interferes with medical training, practice, research, the 
advancement of medical knowledge and enhancement of public’s health.56 
#is was not in the public interest since no other laboratory could assess 
the reliability of its tests, improve upon their speed or cost reducing the 
quality of genetic testing.57 #e e"ects of this patent law blocked people’s 
ability to utilize the health care service that was developed by Myriad in the 
$rst place, leaving it unavailable to many patients and unable to be further 
developed by outside research.
Once the result of these patent’s human rights violations against peo-
ple’s ability to receive health care were brought to the forefront, the court 
reconsidered its rational for allowing human genetics to be patented. #e 
Department of Justice backed the plainti"’s argument by $lling a friend-of-
the-court brief pointing out that DNA extracted from the body was no more 
patent-eligible than any of the natural elements in the periodic table that had 
to be separated chemically from the compounds in which they occur in the 
earth.58 #e case was brought to the Supreme Court who decided in June 
2013 that genomic DNA is ineligible for patenting under the “product of 
nature” doctrine holding that preexisting substances found in the wild may 
not be patented and that Myriad had “not created anything.”59 #e court 
took a more favorable view of cDNA observing that it is a distinct form 
of DNA from which it was derived and could therefore be patented. #is 
decision against the patenting of human genes ruled that $ve out of Myriad’s 
seven patents were not eligible. Additionally, more than 8,000 genes patents 
have the potential to be at risk due to this decision.60 #is ruling is expected 
to make it di!cult for inventors to protect early, gene-related discoveries 
through the patent system. In particular, how the courts will apply this 
decision to other biologic products. #is ruling is a win for patients now 
having greater access to genetic testing and bene$ting from scientists ability 
56  Michelle K. Lee, “Guidance for Determining Subject Matter Eligibility of Claims Re-
citing or Involving Laws of Nature, Natural Phenomena and Natural Products,” College of 
American Pathologists, June 22, 2014.
57  Op. Cit., fn. 51
58  Op. Cit., fn. 46
59  Ibid.  
60  Op. Cit., fn. 55
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to now engage in research on these genes without fear of being sued.61 #is 
was the $rst case to examine patent laws under a human rights scope and 
once the restrictions that these laws created were brought to court, the court 
unanimously decided against the ability to patent human genetic material. 
#e Myriad holding will have far-reaching and long-term implications for 
international patent law. #e United States being a global hegemon, espe-
cially in holding patent laws, means that its Supreme Court decision on the 
Myriad matter is likely to be a leader for other jurisdictions to follow similar 
standards. #is decision sets the United States apart from economic rivals 
when it comes to rules on patenting genes. For example, the European Patent 
O!ce (EPO) grants patents for inventions related to gene sequencing as long 
as applicants can demonstrate the industrial application of the sequence.62 
Australia, Canada and Japan have similar rules, allowing the patenting of 
human genes as long as they are isolated and the patent application explains 
how the genes are useful.63 #ese jurisdictional di"erences means that the 
U.S. Supreme court decision does not directly impact patents in these ju-
risdictions, however the ruling has already made other countries reconsider 
their patent standards. In 2014, a Canadian Children’s Hospital of Eastern 
Ontario $led a court challenge with the ultimate goal of invalidating patents 
on human genes, the $rst court challenge to the country’s Patent Act, which 
is hoping to follow the U.S. Supreme Court’s case rational for striking down 
these patents.64 #e global implications of the Myriad decision create a new 
revelation of viewing patent laws as having the potential to be viewed as a 
human rights issue which could greatly a"ect the way all patents are seen. 
So What? Research Implications 
#e implications of my research $ndings display that there is a crucial 
need to re-evaluate the e"ects that intellectual property rights impose. #e 
technology is available to provide developed and developing nations with 
access to medicines and treatments that could save millions of su"ering 
61  Emma Barraclough, “What Myriad Means for Biotech,” World Intellectual Property Orga-
nization, August 2013.
62  Ibid.
63  Ibid. 
64  Sheryl Ubelacker, “Human DNA Patents Challenged By Canadian Hospital,” !e Hu"-
ington Post, November 3, 2014.
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lives, yet it is unutilized to its full extent due to intellectual property laws 
giving corporations the right to maximize its pro$t. #e ability to invalidate 
patents, as well as their human rights restrictions, when examining the e"ects 
they impose on peoples access to treatment displays that this new method of 
evaluation could have a large in&uence on what is patentable internationally. 
#e development of a human rights framework for intellectual property can 
provide government o!cials, international jurists, and states an opportunity 
to in&uence the framework’s substantive content and the procedural rules 
that mediate relationships between these two components. 
#e International Covenant on Economic, Social and Cultural Rights 
(ICESCR) has been a major international human rights instrument ad-
dressing the issue that patent laws should allow everyone to both “enjoy the 
bene$ts of scienti$c progress and its applications” and “enjoy the bene$t 
from the protection of the moral and material interests resulting from any 
scienti$c, literary or artistic production.”65 #is research brings to light how 
patent laws are beginning to be looked at as human rights issues yet, still 
have a ways to go to ensure that access to health is achieved for everyone. 
#e trend of examining the importance of human rights has been on the rise 
since World War II. With increased knowledge from globalization on these 
issues coupled with this research’s implications of restrictions on health, these 
$ndings have the ability to reshape international law and increase access to 
the bene$ts of scienti$c innovations. 
65  International Covenant on Economic, Social and Cultural Rights, adopted 16 December 
1966, 993 U.N.T.S. 3 (entered into force 3 January 1976), G.A. Res. 2200 (XXI), 21 U.N. 
GAOR Supp. (No. 16), p. 49, U.N. Doc. A/6316 (1966).
